

Notice of Results

31 Oct 2018

REDX PHARMA PLC

(“Redx” or “the Company”)

Notice of Results

Alderley Park, 31 October 2018 Redx (AIM: REDX), the drug development company focused on cancer and fibrosis, will announce its preliminary results for the year ended 30 September 2018 on Monday 19 November 2018.

For further information, please contact:

Redx Pharma Plc

T: +44 1625 469
920

Lisa Anson, Chief Executive Officer

Cantor Fitzgerald Europe (Nominated Advisor & Broker)

T: +44 20 7894
7000

Phil Davies

WG Partners LLP (Joint Broker)

T: +44 20 3705
9330

Claes Spång/ Chris Lee/ David Wilson

FTI Consulting

T: +44 20 3727
1000

Simon Conway/Stephanie Cuthbert

About Redx Pharma Plc

Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

If you would like to sign up to regular alerts from Redx Pharma, please follow this link <https://www.redxpharma.com/investors/email-alerts/>.